Next 10 |
2024-05-10 08:07:35 ET More on HilleVax HilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued Valuation Seeking Alpha’s Quant Rating on HilleVax Historical earnings data for HilleVax Financial information for HilleVax Read the ful...
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmac...
2024-04-12 04:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-22 13:55:54 ET Summary HilleVax, Inc. top line results from the phase 2/3 NEST-IN1 study, using HIL-214 for the prevention of Norovirus-related gastroenteritis, expected mid-2024. Several other studies have already been initiated using HIL-214 for the prevention of Norovir...
2024-03-20 17:04:40 ET More on HilleVax Seeking Alpha’s Quant Rating on HilleVax Historical earnings data for HilleVax Financial information for HilleVax Read the full article on Seeking Alpha For further details see: HilleVax GAAP EPS of -...
2024-03-20 17:02:59 ET More on HilleVax Seeking Alpha’s Quant Rating on HilleVax Read the full article on Seeking Alpha For further details see: HilleVax files $500M mixed securities shelf
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable securities as of December 31, 2023 BOSTON, March 20, 2024 (GLOBE NEWSWIRE)...
Tredegar Corporation (TG) is expected to report for quarter end 2023-12-31 Pharma-Bio Serv Inc (PBSV) is expected to report $0.02 for Q1 2024 Telos Corporation (TLS) is expected to report $-0.18 for Q4 2023 Coretec Group Inc (CRTG) is expected to report for quarter end 2023-12-31 ...
2024-03-02 13:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-10 02:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
HilleVax Inc. Company Name:
HLVX Stock Symbol:
NASDAQ Market:
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmac...
2024-04-12 04:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable securities as of December 31, 2023 BOSTON, March 20, 2024 (GLOBE NEWSWIRE)...